Accueil>>Signaling Pathways>> Apoptosis>> p53>>Cjoc42

Cjoc42

Catalog No.GC64649

Cjoc42 est un composé capable de se lier À la gankyrine. Cjoc42 inhibe l'activité de la gankyrine de manière dose-dépendante. Cjoc42 empêche la diminution des niveaux de protéine p53 normalement associée À des quantités élevées de gankyrine. Cjoc42 restaure la transcription dépendante de p53 et la sensibilité aux dommages À l'ADN.

Products are for research use only. Not for human use. We do not sell to patients.

Cjoc42 Chemical Structure

Cas No.: 2171519-89-2

Taille Prix Stock Qté
5 mg
324,00 $US
En stock
10 mg
522,00 $US
En stock
25 mg
1 035,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Cjoc42 is a compound capable of binding to gankyrin. Cjoc42 inhibits gankyrin activity in a dose-dependent manner. Cjoc42 prevents the decrease in p53 protein levels normally associated with high amounts of gankyrin. Cjoc42 restores p53-dependent transcription and sensitivity to DNA damage[1].

cjoc42 (0.5, 1, and 5 μM; 48 hours) dose-dependently restores p53 levels (comparable to mock transfected cells) and inhibits gankyrin-induced lowering of p53 levels in cells[1].cjoc42 (0.1, 1, and 10 μM; 24 hours) alone shows no dose-dependent change in cell viability[1].

[1]. Chattopadhyay A, et al. Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell. Sci Rep. 2016;6:23732.

Avis

Review for Cjoc42

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Cjoc42

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.